Literature DB >> 17978418

Direct monitoring pressure overload predicts cardiac hypertrophy in mice.

Sheng Zhong Duan1, Christine Y Ivashchenko, Steven E Whitesall, Louis G D'Alecy, Richard M Mortensen.   

Abstract

Pressure overload (POL) is a classical model for studying cardiac hypertrophy, but there has been no direct measure of hemodynamics in a conscious ambulatory mouse model of POL. We used abdominal aortic constriction to produce POL and radiotelemetry to measure the blood pressure and heart rate for three weeks. The cardiac size correlated with the systolic pressure in the last week is better than other hemodynamic parameters. Cardiac fibrosis was more correlated to the cardiac size than to the systolic pressure. The expression of the cardiac genes that are typically associated with cardiac hypertrophy was correlated with both cardiac size and systolic pressure. In conclusion, the systolic pressure is the major determinant of cardiac hypertrophy in the murine POL model. In contrast, cardiac fibrosis shows the influence of other factors besides systolic pressure. The combination of the POL model with continuous direct measurements of hemodynamics represents a significant technological advance and will lead to an extended usefulness of POL methodologically.

Entities:  

Mesh:

Year:  2007        PMID: 17978418     DOI: 10.1088/0967-3334/28/11/001

Source DB:  PubMed          Journal:  Physiol Meas        ISSN: 0967-3334            Impact factor:   2.833


  2 in total

1.  Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice.

Authors:  Chao Li; Yu Yao Zhang; Ryan A Frieler; Xiao Jun Zheng; Wu Chang Zhang; Xue Nan Sun; Qing Zhen Yang; Shu Min Ma; Baozhuan Huang; Stefan Berger; Wang Wang; Yong Wu; Ying Yu; Sheng Zhong Duan; Richard M Mortensen
Journal:  PLoS One       Date:  2014-10-29       Impact factor: 3.240

2.  Dapagliflozin Mediates Plin5/PPARα Signaling Axis to Attenuate Cardiac Hypertrophy.

Authors:  Jing Yu; Huanhuan Zhao; Xin Qi; Liping Wei; Zihao Li; Chunpeng Li; Xiaoying Zhang; Hao Wu
Journal:  Front Pharmacol       Date:  2021-09-23       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.